PRINCETON, N.J., April  07, 2026  (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN®

ANIP

ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

Publication of ILUVIEN trial results boosts ANI Pharmaceuticals' visibility

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN®
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 ANI Pharmaceuticals published encouraging results from the NEW DAY clinical trial for ILUVIEN in Ophthalmology, targeting diabetic macular edema. This publication serves to enhance credibility within the ophthalmology community and may positively impact market acceptance of ILUVIEN, which face notable contraindications and side effects.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>ILUVIEN trial results published in the journal Ophthalmology.</li><li>This study targets diabetic macular edema, enhancing drug credibility.</li><li>ILUVIEN shows potential despite contraindications and side effects.</li><li>Report presents ongoing commitment to clinical data generation.</li><li>Market response may evolve with ILUVIEN&#039;s adoption rate.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>ANI Pharmaceuticals (ANIP): The company relies on ILUVIEN for growth.</li><li>Ophthalmology Journal: Publication in this journal enhances ANIP&#039;s credibility.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 The article fits in &#039;Corporate Developments&#039; due to the significant clinical trial results publication, showcasing ANI Pharmaceuticals&#039; engagement in advancing ophthalmic therapies and addressing key health issues like diabetic macular edema.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Positive reception of ILUVIEN could drive sales growth in the ophthalmic segment.</li><li>Regulatory approvals and subsequent market acceptance remain key price drivers.</li><li>Adverse reactions reported may affect investor sentiment and product uptake.</li><li>Increased visibility from publication could attract new institutional investors.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>ILUVIEN is used to treat diabetic macular edema.</li><li>84% of ILUVIEN patients experienced adverse reactions.</li><li>Publication in Ophthalmology emphasizes clinical commitment.</li><li>Trial results announced in July 2025; published April 2026.</li><li>34% of ILUVIEN patients had increased intraocular pressure.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider a bullish position in ANIP based on potential ILUVIEN market uptake over the next 12 months.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ANIP">ANIP</a>) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN&#xAE; (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a corticosteroid indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. "We are proud that the results from the NEW DAY clinical trial have been published in Ophthalmology, a leading, globally respected peer-reviewed journal," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "This publication represents our team's continued commitment to generating clinical data for patients living with DME and for the overall retina community." The published research article is currently available on the Ophthalmology website titled: "Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study." IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS <ul type="disc"><li>ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.</li><li>ILUVIEN is contraindicated in patients with glaucoma who have cup to disc ratios of greater than 0.8.</li><li>ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product. </li></ul> WARNINGS AND PRECAUTIONS <ul type="disc"><li>Intravitreal Injection-related Effects: Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Patients should be monitored following the intravitreal injection. Patients may experience temporary blurred vision after injection of the implant.</li><li>Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in the development of glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be routinely monitored during the course of the treatment.</li><li>Cataracts: The use of corticosteroids may result in posterior subcapsular cataract formation.</li><li>Delayed Corneal Wound Healing: The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.</li><li>Corneal and Scleral Melting: Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of ophthalmic corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation of the globe.</li><li>Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.</li><li>Viral Infections: Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.</li><li>Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.</li><li>Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber. </li></ul> ADVERSE REACTIONS Diabetic Macular Edema Ocular adverse reactions reported by greater than or equal to 1% of patients in the two combined 3-year clinical trials following injection of ILUVIEN for diabetic macular edema include: cataract (82%), myodesopsia (21%), eye pain (15%), conjunctival hemorrhage (13%), posterior capsule opacification (9%), eye irritation (8%), vitreous detachment (7%), conjunctivitis (4%), corneal oedema (4%), foreign body sensation in eyes (3%), eye pruritus (3%), ocular hyperaemia (3%), optic atrophy (2%), ocular discomfort (2%), photophobia (2%), retinal exudates (2%), anterior chamber cell (2%), and eye discharge (2%). Non-ocular adverse reactions reported by greater than or equal to 5% of patients include: anemia (11%), headache (9%), renal failure (9%), and pneumonia (7%). Increased Intraocular Pressure: IOP elevation greater than or equal to 10 mm Hg from baseline at any visit was seen in 34% of ILUVIEN patients versus 10% of sham patients. IOP elevation greater than or equal to 30 mm Hg was seen in 20% of ILUVIEN patients versus 4% of sham patients. 38% of the patients who received ILUVIEN were subsequently treated with IOP-lowering medications during the study versus 14% of sham patients. 5% of the patients who received ILUVIEN needed surgical intervention for elevated IOP versus 1% of sham patients. Cataracts and Cataract Surgery: The incidence of cataract development in patients who had a phakic study eye was higher in the ILUVIEN group (82%) compared with sham (50%). The median time of cataract being reported as an adverse event was approximately 12 months in the ILUVIEN group and 19 months in the sham group. Among these patients, 80% of ILUVIEN subjects versus 27% of sham-controlled subjects underwent cataract surgery, generally within the first 18 months (median month 15 for both ILUVIEN group and for sham) of the studies. Please see full <a href="https://www.globenewswire.com/Tracker?data=bpgTcGlhnWUv0riIjXERgTZz3ZR9XAzT77r-zmEf5oHM5rlxmOFd1DP6qSLN3_AqBzuB3UQDdI1hKQ6iU1jS14CPSnGY2IdKJ3ZaFgJbKigDBHqe5S_gpsOXD3fAnQEfEO-qmDRVfRgYL_RlNihPKA==" rel="nofollow" target="_blank">Prescribing Information</a>. About ANI ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ANIP">ANIP</a>) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives&#34; by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&amp;D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=MUJCFpdCzXoOdtsM02AXS4GhtFdkCghjbBLSgzUFSkuTO_0Cnq-3_DD_IfPkmkO3eQHBA-i6z_v4gO-a7zJk2K2Fo7E6QRpnoZOsQUiD9OC9Cd-XuCKMKb_ASTuawSA3" rel="nofollow" target="_blank">www.anipharmaceuticals.com</a>. Forward-Looking Statements To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company's strategy; its plans with respect to the commercialization and potential sales of the Company's products, including current and planned product launches and any additional product launches from the Company's generic pipeline; expansion plans for the Rare Disease business, including with respect to the planned expansion of the Company's sales force for acute gouty arthritis; anticipated growth opportunities for ILUVIEN; anticipated R&amp;D developments and clinical trial advances; and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates. Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company's approved products, including ILUVIEN, to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; delays and disruptions in the production of the Company's approved products; increased costs and potential loss of revenues if the Company needs to change suppliers due to the limited number of suppliers for its raw materials, active pharmaceutical ingredients, expedients, and other materials; delays and disruptions in the production of the Company's approved products as a result of its reliance on single source third party contract manufacturing supply for certain of its key products, including ILUVIEN; delays or failure to obtain or maintain approvals by the FDA of the Company's products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company's products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of the Company's manufacturing partners to meet its product demands and timelines; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the Company's ability to protect its intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company's ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; ; and general business and economic conditions, such as inflationary pressures, geopolitical conditions. More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Relations: Courtney Mogerley, Argot Partners T: 646-368-8014 E: <a href="https://www.globenewswire.com/Tracker?data=Pb4-ScQhl6o99lGQPTHnpayFOxavS_DLDiaYQLEYV14dDnvPmUWD9aAhSofuyJEyPwCet35OMYzgKp3LTvJJdHmiWo-FnksWXhWFPfVWmdo=" rel="nofollow" target="_blank">ani@argotpartners.com</a> Media Relations: Argot Partners T: 212-600-1494 E: <a href="https://www.globenewswire.com/Tracker?data=Pb4-ScQhl6o99lGQPTHnpayFOxavS_DLDiaYQLEYV15ARYk-1mxSkzitlRv1FAEOrYTAtwtpda7r5IUAQESLGYeGl08istQ_LwyyMaFgmrQ=" rel="nofollow" target="_blank">ani@argotpartners.com</a> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NDczNiM3NTIxNDcyIzIwMTkyNjA="></img> <img alt="" src="https://ml.globenewswire.com/media/YzdmMDY5MWUtZWVlZS00NjRhLWFjNzctYWEwM2M2NzQyODFiLTEwMzA4MzMtMjAyNi0wNC0wNy1lbg==/tiny/ANI-Pharmaceuticals-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/24d1d851-9075-4d6e-b22c-0c23a5ef0b36"><img src="https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png" border="0" width="150" height="63" alt="Primary Logo"></img></a>

ANI Pharmaceuticals published encouraging results from the NEW DAY clinical trial for ILUVIEN in Ophthalmology, targeting diabetic macular edema. This publication serves to enhance credibility within the ophthalmology community and may positively impact market acceptance of ILUVIEN, which face notable contraindications and side effects.

ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News